APSR2026-177

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-028
P47
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1212386-46904-APSR26_Poster last1_434582.pdf
Format: PDF Only
08. Lung Cancer
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Hirofumi Nakano * Fukuoka seisyukai hospital Respiratory Medicine Fukuoka Japan
Eri Yasue - Fukuoka seisyukai hospital Respiratory Medicine Fukuoka Japan Self-Defense Forces Fukuoka Hospital Internal Medicine Fukuoka Japan
Yu Tsukasa - Fukuoka seisyukai hospital Respiratory Medicine Fukuoka Japan Self-Defense Forces Fukuoka Hospital Internal Medicine Fukuoka Japan
Takayuki Yamamoto - Fukuoka seisyukai hospital Respiratory Medicine Fukuoka Japan
Ryota Aoki - Fukuoka seisyukai hospital Respiratory Medicine Fukuoka Japan
Yukihiro Sugimoto - Fukuoka seisyukai hospital Respiratory Medicine Fukuoka Japan
Sosei Abe - Fukuoka seisyukai hospital surgery Fukuoka Japan
Masanori Takayama - Fukuoka seisyukai hospital Respiratory Medicine Fukuoka Japan
 
 
 
 
 
 
 
Presenting Author Details
Hirofumi
Nakano
h.nakano@seisyukai.jp
+819030161133
51-60
Japan
Case Report
A case of complete response to nivolumab plus platinum-based neoadjuvant chemotherapy in mediastinal carcinoma of unknown primary with KRAS G12C mutation
Maximum 25 words
Abstract Content
 
 
 
 
the use of neoadjuvant chemotherapy, including immune checkpoint inhibitors, for carcinoma of unknown primary origin remains limited. and、KRAS G12C mutations have been noted to be highly associated with smoking.
62-year-old male. undergoing outpatient treatment at a local hospital for chronic obstructive pulmonary disease and hypertension. history of smoking.presenting to our emergency department with dyspnea as the chief complaint.chest CT revealed mediastinal lymph node enlargement.EBUS-TBNA performed for mediastinal lymph node #4.diagnosis of KRAS G12C mutation-positive adenocarcinoma. PDL1 > 75%. tumor marker CEA 130 ng/dL.PET/CT revealed no significant primary lesions. considered equivalent to T0 lung cancer、as preoperative chemotherapy, nivolumab 360 mg/body + cisplatin 75mg/m² + pemetrexed 500 mg/m² were administered every 3 weeks for three cycles. Imaging showed tumor shrinkage, and the CEA 4.5ng/ml.following anticancer drug therapy and after chemotherapy, a thoracoscopic lymph node dissection was performed. pathology revealed no malignant findings, resulting in a complete response.
we report a case of mediastinal lymph node carcinoma of unknown primary that achieved complete response following neoadjuvant chemotherapy including an immune checkpoint inhibitor. consideration of the appropriate timing for administration of immune checkpoint inhibitors and their efficacy against KRAS mutations.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
carcinoma of unknown primary、neoadjuvant chemotherapy、nivolumab
maximum 3 keywords and no abbreviations, separated by commas
 
198